Change at the top for Biogen after Alzheimer's drug flops
Biogen will replace its CEO and largely abandon marketing of its controversial Alzheimer's drug Aduhelm.
More from Michigan Business
DetroitNews Business
US stocks slip as investors weigh economic data, Fed policy
Michigan Business
•
Dec 5, 2022
DetroitNews Business
Sale jumpstarts floating, offshore wind power in US waters
Michigan Business
•
Dec 5, 2022
DetroitNews Business
Stocks open lower on Wall Street, crude oil prices climb
Michigan Business
•
Dec 5, 2022
Michigan Lawyers Weekly
Reformers take 6 of 14 UAW board seats, could win majority
Michigan Business
•
Dec 5, 2022
Michigan Lawyers Weekly
Tolling exception to one-year-back rule readopted
Michigan Business
•
Dec 5, 2022
DetroitNews Business
India signals it will continue to buy oil from Russia
Michigan Business
•
Dec 5, 2022
DetroitNews Business
As Musk is learning, content moderation is a messy job
Michigan Business
•
Dec 5, 2022
DetroitNews Business
Elon Musk says Apple is 'fully' advertising on Twitter again
Michigan Business
•
Dec 4, 2022